Intratympanic Steroids for Sudden Hearing Loss

Intratympanic Dexamethasone or Methylprednisolone for Sudden Hearing Loss as a Salvage Treatment: a Randomized, Double-blind, Multi-center Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04129697

Enrollment

Registered

2019-10-17

Start date

2020-01-01

Completion date

2022-12-31

Last updated

2019-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dexamethasone or Methylprednisolone; Sudden Hearing Loss; Intratympanic Steroid

Brief summary

For patients with sudden hearing loss, the initial treatment is not usually effective. We use Dexamethasone or Methylprednisolone to be an Intratympanic steroid administration as a salvage treatment. An randomized, double-blind, multi-center study is designed to find the difference between Dexamethasone or Methylprednisolone.

Interventions

DRUGDexamethasone or Methylprednisolone

steroids

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

sudden hearing loss and initial treatment is not effective

Exclusion criteria

the patients refused intratympanic steroids treatment.

Design outcomes

Primary

Measure	Time frame	Description
hearing	six month	the hearing level after treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026